Indications and Limitations of Use
Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis.
EPOGEN® (epoetin alfa) is indicated for the treatment of anemia due to chronic kidney disease (CKD) in patients on dialysis to decrease the need for red blood cell (RBC) transfusion.
Limitations of Use:
- Aranesp® and EPOGEN® have not been shown to improve quality of life, fatigue, or patient well-being.
- Aranesp® and EPOGEN® are not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.
Please click to see accompanying Aranesp® full prescribing information and EPOGEN® full prescribing information, including Boxed WARNINGS and Medication Guide.